#United States #financial results #Belgrade #Surgical Solutions #Xtant Medical

Xtant Medical's Strong Financial Performance in 2025

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in medical technology, has reported outstanding financial results for the fourth quarter and full year ending December 31, 2025. The company has marked a significant revenue increase, fueling its strategic growth initiatives. In Q4 2025, Xtant generated revenue amounting to $32.4 million, which represents a 3% increase compared to the same period in the previous year. The full-year revenue stood at $134 million, showcasing a remarkable 14% growth from 2024.

A key highlight from their fourth quarter results is the substantial gross margin, which climbed to 54.9%, an increase from 50.8% year-over-year. This growth in margin reflects effective cost management and an improved sales mix. Most encouragingly, Xtant achieved a net income of $0.1 million in Q4, a turnaround from a net loss of $3.2 million during the same quarter last year. This improved financial standing was bolstered by a non-GAAP adjusted EBITDA of $1.9 million, compared to just $0.4 million in Q4 2024.

In terms of year-long achievements, Xtant Medical successfully closed out 2025 with a net income of $5 million, which translates to $0.03 per diluted share. This stark contrast to the net loss of $16.5 million in 2024 further solidifies the company's recovery and strategic focus on its core biologics business. Their gross margin for the entire year also improved to 62.9%, from 58.2% the previous year, indicating effective scalability and operational efficiency.

Highlights of Recent Business Developments

The successful sale of non-core assets, specifically the Coflex® and CoFix products, to Companion Spine has played a pivotal role in Xtant's performance. This transaction, worth $21.4 million, aimed to streamline the company’s operations and refocus its efforts on biologic innovations. Following this divestiture, Xtant’s operational cash flow turned positive, amounting to $12.5 million, a marked improvement from a cash deficit in 2024.

In addition to its robust financial outcomes, Xtant Medical launched several innovative products in their nanOss line, including the next-generation synthetic bone graft Strata™, along with the CollagenX™ product designed for surgical wound closure. These new offerings are expected to enhance their market position and cater to evolving surgical needs.

Sean Browne, the President and CEO of Xtant Medical, expressed optimism about the future, highlighting plans for further growth: "2025 was a transformative year where we not only achieved profitability but also enhanced our innovative edge in biologics. Our focus will now pivot towards constructing a stronger commercial team, leveraging our existing product portfolio to maximize efficiency in growth."

Looking Ahead to 2026

With the cash position exceeding $22 million and a reduced term loan balance of $11.2 million, Xtant Medical is well-positioned to further its growth trajectory in 2026. The company anticipates a revenue range of $95 million to $99 million in 2026, with expectations for sustained organic growth within its core biologics sector.

Apart from positive financial forecasts, Xtant is also committed to capitalizing on the strengthened cash flow to expand their sales force—a strategic move designed to enhance market reach and optimize sales performance in a competitive landscape.

The latest developments and outcomes for Xtant Medical reinforce the transformative potential of innovative solutions in the health sector. As the medical technology landscape continues to evolve, Xtant remains committed to delivering superior surgical solutions, advancing patient outcomes, and fulfilling their core mission of utilizing donations for improving lives globally.